Treatment patterns and clinical outcomes in hospitalized adults with discordant Clostridioides difficile results: a multihospital cohort study

Clostridioides difficile infection (CDI) is a common gastrointestinal infection in hospitalized patients. A two-step testing algorithm comprised of a nucleic acid amplification test (NAAT) followed by a specific toxin assay may be used to improve diagnostic accuracy of infection testing. Discordant results (NAAT+/Toxin-), however, create clinical uncertainty regarding the administration of CDI antimicrobial therapy. The purpose of this retrospective cohort study was to identify predictors of adverse clinical outcomes, including administration of CDI antimicrobial therapy as a primary predictor of interest, and evaluate treatment patterns among hospitalized adults with discordant C. difficile test results. This study included hospitalized adults with discordant (NAAT+/Toxin-) C. difficile test results between December 2023 and June 2025 across a nine-hospital tertiary-care health system. The primary outcome was a composite endpoint of 30-day all-cause mortality and colectomy attributable to C. difficile. Secondary outcomes included receipt of CDI antimicrobial therapy and 30-day all-cause readmission to an acute-care facility. Multivariable logistic regression identified factors associated with clinical outcomes and antimicrobial therapy. Among 1,256 patients with discordant C. difficile testing, the primary composite outcome occurred in 59 (5%) patients. Factors associated with the primary outcome included older age (65–99 years; odds ratio (OR) 2.95, [1.53–6.20], p < 0.01), immunocompromised status within 30 days prior to the discordant test (OR 2.08, [1.10–4.15], p = 0.03), white blood cell counts ≥ 15,000 cells/µL (OR 1.86, [1.05–3.26], p = 0.03), and intensive care unit (ICU) status at the time of the C. difficile discordant test (OR 3.49, [1.91–6.29], p < 0.01). Overall, 879 (70%) patients received antimicrobial therapy; in exploratory analyses, ICU status was associated with treatment receipt (OR 1.50, 95% CI 1.02–2.24). Thirty-day readmission was associated with immunocompromised status (OR 1.68, 95% CI 1.25–2.26), elevated creatinine levels (OR 1.48, 95% CI 1.12–1.96), and higher comorbidity index (OR 2.03, 95% CI 1.34–3.14), and older age was associated with lower odds of readmission (OR 0.75, 95% CI 0.57–0.99). Patient-level clinical characteristics and markers of acute illness, rather than discordant CDI test results alone, are more strongly associated with short-term clinical outcomes. CDI antimicrobial therapy was not independently associated with the primary composite outcome among patients with discordant C. difficile test results after adjustment for measured confounders. Future studies are needed to determine whether specific groups of patients with discordant results benefit from treatment.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-21
DOI
https://doi.org/10.1038/s41598-026-82036-1
Primary Topic
Clostridium difficile and Clostridium perfringens research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Treatment patterns and clinical outcomes in hospitalized adults with discordant Clostridioides difficile results: a multihospital cohort study

Muhammad Yasser Alsafadi, Oscar Noble, Jesus Paez‐Mayorga, Christopher Fan et al.
Scientific Reports
Clostridium difficile and Clostridium perfringens research
article

Treatment patterns and clinical outcomes in hospitalized adults with discordant Clostridioides difficile results: a multihospital cohort study

Muhammad Yasser Alsafadi, Oscar Noble, Jesus Paez‐Mayorga, Christopher Fan, Poojasree Pasupuleti, Shemual Tsai
article en

Abstract

Clostridioides difficile infection (CDI) is a common gastrointestinal infection in hospitalized patients. A two-step testing algorithm comprised of a nucleic acid amplification test (NAAT) followed by a specific toxin assay may be used to improve diagnostic accuracy of infection testing. Discordant results (NAAT+/Toxin-), however, create clinical uncertainty regarding the administration of CDI antimicrobial therapy. The purpose of this retrospective cohort study was to identify predictors of adverse clinical outcomes, including administration of CDI antimicrobial therapy as a primary predictor of interest, and evaluate treatment patterns among hospitalized adults with discordant C. difficile test results. This study included hospitalized adults with discordant (NAAT+/Toxin-) C. difficile test results between December 2023 and June 2025 across a nine-hospital tertiary-care health system. The primary outcome was a composite endpoint of 30-day all-cause mortality and colectomy attributable to C. difficile. Secondary outcomes included receipt of CDI antimicrobial therapy and 30-day all-cause readmission to an acute-care facility. Multivariable logistic regression identified factors associated with clinical outcomes and antimicrobial therapy. Among 1,256 patients with discordant C. difficile testing, the primary composite outcome occurred in 59 (5%) patients. Factors associated with the primary outcome included older age (65–99 years; odds ratio (OR) 2.95, [1.53–6.20], p < 0.01), immunocompromised status within 30 days prior to the discordant test (OR 2.08, [1.10–4.15], p = 0.03), white blood cell counts ≥ 15,000 cells/µL (OR 1.86, [1.05–3.26], p = 0.03), and intensive care unit (ICU) status at the time of the C. difficile discordant test (OR 3.49, [1.91–6.29], p < 0.01). Overall, 879 (70%) patients received antimicrobial therapy; in exploratory analyses, ICU status was associated with treatment receipt (OR 1.50, 95% CI 1.02–2.24). Thirty-day readmission was associated with immunocompromised status (OR 1.68, 95% CI 1.25–2.26), elevated creatinine levels (OR 1.48, 95% CI 1.12–1.96), and higher comorbidity index (OR 2.03, 95% CI 1.34–3.14), and older age was associated with lower odds of readmission (OR 0.75, 95% CI 0.57–0.99). Patient-level clinical characteristics and markers of acute illness, rather than discordant CDI test results alone, are more strongly associated with short-term clinical outcomes. CDI antimicrobial therapy was not independently associated with the primary composite outcome among patients with discordant C. difficile test results after adjustment for measured confounders. Future studies are needed to determine whether specific groups of patients with discordant results benefit from treatment.

Scientific Reports
Houston Methodist (US), Cornell University (US), Methodist Hospital (US), Methodist Hospital (US), Weill Cornell Medicine (US)
Clostridium difficile and Clostridium perfringens research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon